Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

REGENERON PHARMACEUTICALS, INC. Director's Dealing 2017

May 26, 2017

29977_dirs_2017-05-26_36949758-83aa-44a1-97c9-326fb2ec3bdd.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2017-05-25

Reporting Person: VAGELOS P ROY (Director, Chairman of the Board)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-01-03 Common Stock G 571 $0.0 Disposed 151254 Indirect
2017-04-03 Common Stock G 547 $0.0 Disposed 150707 Indirect
2017-05-25 Common Stock S 3510 $457.58 Disposed 89437 Indirect
2017-05-25 Common Stock S 4985 $458.35 Disposed 84452 Indirect
2017-05-25 Common Stock S 800 $459.24 Disposed 83652 Indirect

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 414156 Direct
Common Stock 2300 Indirect
Common Stock 1203 Indirect

Footnotes

F1: Represents volume-weighted average price of sales of 3,510 shares of Company stock on May 25, 2017 at prices ranging from $457.05 to $457.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 25, 2017 at each separate price.

F2: Represents volume-weighted average price of sales of 4,985 shares of Company stock on May 25, 2017 at prices ranging from $458.00 to $458.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 25, 2017 at each separate price.

F3: Represents volume-weighted average price of sales of 800 shares of Company stock on May 25, 2017 at prices ranging from $459.01 to $459.53. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 25, 2017 at each separate price.

F4: By a trust for the benefit of certain grandchildren of the reporting person, of which the reporting person and/or the spouse of the reporting person is trustee.